Huayuan Securities recently released a research report suggesting that the humanoid robot industry may gradually transition from small-scale validation to a new '1-10' phase. According to Jin10, the report recommends focusing on upstream components and main manufacturers. Upstream components are expected to benefit first due to cost advantages. For main manufacturers, increased production and capitalization are likely to lead to full valuation pricing. However, the report also warns of potential risks, including slower-than-expected progress, lower-than-expected sales, and deteriorating industry policies and competition.